CPA
ADPT icon

Capital Performance Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

Capital Performance Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-764
Closed -$3.91K – 209
2024
Q3 		$3.91K Buy
+764
New +$3.33K ﹤0.01% 1219

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital Performance Advisors's ADPT Position: Q4 2024 in Review

Capital Performance Advisors sold out of Adaptive Biotechnologies (ADPT) in Q4 2024, closing a stake of 764 shares — an estimated $3.91K sold.

Capital Performance Advisors first reported a position in ADPT in Q3 2024 and held it in 1 quarter. The position peaked at $3.91K in Q3 2024. 207 funds tracked by Wall St. Rank hold ADPT as of Q4 2024.

  • Capital Performance Advisors reported no remaining Adaptive Biotechnologies position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 764 Adaptive Biotechnologies shares in Q4 2024, an estimated $3.91K.
  • Capital Performance Advisors first reported a position in Adaptive Biotechnologies in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Adaptive Biotechnologies position peaked at $3.91K in Q3 2024.
  • 207 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.